Jonathan Schoenecker
Last active: 2/22/2016


My research laboratory is dedicated to define the integrated role of coagulation and inflammation on orthopaedic related wound healing. My unique focus stems from my surgical training in musculoskeletal diseases in combination with my basic science training in coagulation and bone biology. Our initial experiments have employed models of bone growth, tumor and wound healing to characterize and manipulate cell membrane associated coagulation receptors including tissue factor, thrombomodulin and protease activated receptors. Utilizing these same models, we are investigating how the currently used coagulation associated orthobiologics affect bone growth. Over the next 5-10 years I propose to develop novel coagulation based pharmaceuticals capable of manipulating fracture healing in osteoporotic bone or inhibiting bone based tumors and infections. Clinically, we are developing new measures of coagulation to quantify hypercoaguability. Current clinical tests of coagulation are incapable of quantifying hypercoaguability. Instead, it can only be measured through surrogate markers such as the development of a DVT. These markers represent the end-stage complications of hypercoaguability and are impractical measures. Furthermore, because the extent and duration of orthopaedic and surgically related hypercoaguability has not been reported, it is unknown how long treatment of hypercoaguable plasma with anticoagulation is required. As a result, patients are treated in the post-surgical period with a “standard” dose of anticoagulant due to the absence of methods to inform accurate dosing or duration of therapy. This approach places patients at serious risk for developing complications either from i) under-treatment leaving the patient unprotected from hypercoaguability or ii) over-treatment, putting the patient at risk for hemorrhage, hematoma and complications of traumatic and surgical wound healing. Our preliminary data suggest that thrombin generation assays enable the sensitive detection orthopaedic and surgically related hypercoaguability. Therefore, clinically I propose that utilization of this assay will provide rational dose regiments for anticoagulant therapy for these patients. These studies have been initiated and will likely encompass the next 10 years of my clinical research program. Further, recent evidence suggests that many diseases treated by pediatric orthopaedic surgeons are secondary to a hypercoaguable state, such as; Legg-Calves-Perthes disease, osteosarcoma, osteomyelitis and cerebral palsy. We hope over the next five years to apply our novel clinical test to these diseases with the goal of diagnosing and treating the coagulation aspects of these diseases. The strength of this research program is its uniqueness and clinical relevance. Coagulation research and its pharmaceutical application have already been identified by major cross-disciplinary clinical and research organizations for subject directed funding. The major innovation of this research is that it will i) provide a quantitative measure of hypercoaguability and ii) determine the critical threshold of hypercoaguability that is required for optimal skin and bone wound healing. These studies will have direct and immediate implications for patients undergoing orthopaedic surgery by defining optimal treatment strategies that prevent the complications of the hypercoaguable state, but permit wound healing. They will also allow potentially provide a novel understanding of the pathophysiology of many common diseases specific to pediatric orthopaedics.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Leclercia adecarboxylata Musculoskeletal Infection in an Immune Competent Pediatric Patient: An Emerging Pathogen? Grantham WJ, Funk SS, Schoenecker JG (2015) Case Rep Orthop : 160473
    › Primary publication · 26609458 (PubMed) · PMC4644830 (PubMed Central)
  2. Thrombin induced by the extrinsic pathway and PAR-1 regulated inflammation at the site of fracture repair. Sato N, Ichikawa J, Wako M, Ohba T, Saito M, Sato H, Koyama K, Hagino T, Schoenecker JG, Ando T, Haro H (2016) Bone : 23-34
    › Primary publication · 26475502 (PubMed)
  3. Fibrinolysis is essential for fracture repair and prevention of heterotopic ossification. Yuasa M, Mignemi NA, Nyman JS, Duvall CL, Schwartz HS, Okawa A, Yoshii T, Bhattacharjee G, Zhao C, Bible JE, Obremskey WT, Flick MJ, Degen JL, Barnett JV, Cates JM, Schoenecker JG (2015) J Clin Invest 125(9): 3723
    › Primary publication · 26325037 (PubMed) · PMC4588290 (PubMed Central)
  4. Fibrinolysis is essential for fracture repair and prevention of heterotopic ossification. Yuasa M, Mignemi NA, Nyman JS, Duvall CL, Schwartz HS, Okawa A, Yoshii T, Bhattacharjee G, Zhao C, Bible JE, Obremskey WT, Flick MJ, Degen JL, Barnett JV, Cates JM, Schoenecker JG (2015) J Clin Invest 125(8): 3117-31
    › Primary publication · 26214526 (PubMed) · PMC4563750 (PubMed Central)
  5. Prevalence of Hypertension in Pediatric Tibia Vara and Slipped Capital Femoral Epiphysis. Taussig MD, Powell KP, Cole HA, Nwosu SK, Hunley T, Romine SE, Iwinski H, Talwalkar V, Warhoover T, Lovejoy SA, Mencio GA, Martus JE, Walker J, Milbrandt T, Schoenecker JG (2016) J Pediatr Orthop 36(8): 877-883
    › Primary publication · 26090984 (PubMed)
  6. Symptomatic Accessory Medial Meniscus Associated With Popliteal Pterygium Syndrome. Funk SS, Block JJ, Martus JE, Schoenecker JG (2015) J Pediatr Orthop 35(7): e76-9
    › Primary publication · 25992493 (PubMed)
  7. Bisphosphonates: from softening water to treating PXE. Moore SN, Tanner SB, Schoenecker JG (2015) Cell Cycle 14(9): 1354-5
    › Primary publication · 25894689 (PubMed) · PMC4614008 (PubMed Central)
  8. Stuffed Animals in the Operating Room: A Reservoir of Bacteria With a Simple Solution. Held M, Mignemi M, O'Rear L, Wise M, Zane G, Murphy Zane MS, Schoenecker JG (2015) J Pediatr Orthop 35(8): e110-2
    › Primary publication · 25851680 (PubMed)
  9. Hemiepiphysiodesis Implants for Late-onset Tibia Vara: A Comparison of Cost, Surgical Success, and Implant Failure. Funk SS, Mignemi ME, Schoenecker JG, Lovejoy SA, Mencio GA, Martus JE (2016) J Pediatr Orthop 36(1): 29-35
    › Primary publication · 25551783 (PubMed)
  10. Transglutaminase factor XIII promotes arthritis through mechanisms linked to inflammation and bone erosion. Raghu H, Cruz C, Rewerts CL, Frederick MD, Thornton S, Mullins ES, Schoenecker JG, Degen JL, Flick MJ (2015) Blood 125(3): 427-37
    › Primary publication · 25336631 (PubMed) · PMC4296006 (PubMed Central)
  11. The hyperglycemic byproduct methylglyoxal impairs anticoagulant activity through covalent adduction of antithrombin III. Jacobson R, Mignemi N, Rose K, O'Rear L, Sarilla S, Hamm HE, Barnett JV, Verhamme IM, Schoenecker J (2014) Thromb Res 134(6): 1350-7
    › Primary publication · 25307422 (PubMed) · PMC4337957 (PubMed Central)
  12. The temporal and spatial development of vascularity in a healing displaced fracture. Yuasa M, Mignemi NA, Barnett JV, Cates JM, Nyman JS, Okawa A, Yoshii T, Schwartz HS, Stutz CM, Schoenecker JG (2014) Bone : 208-21
    › Primary publication · 25016962 (PubMed)
  13. Twenty-Year Experience with Rigid Intramedullary Nailing of Femoral Shaft Fractures in Skeletally Immature Patients. Crosby SN, Kim EJ, Koehler DM, Rohmiller MT, Mencio GA, Green NE, Lovejoy SA, Schoenecker JG, Martus JE (2014) J Bone Joint Surg Am 96(13): 1080-1089
    › Primary publication · 24990973 (PubMed)
  14. Micro-computed tomography derived anisotropy detects tumor provoked deviations in bone in an orthotopic osteosarcoma murine model. Cole HA, Ohba T, Ichikawa J, Nyman JS, Cates JM, Haro H, Schwartz HS, Schoenecker JG (2014) PLoS One 9(6): e97381
    › Primary publication · 24892952 (PubMed) · PMC4043681 (PubMed Central)
  15. Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma. Ohba T, Cates JM, Cole HA, Slosky DA, Haro H, Ando T, Schwartz HS, Schoenecker JG (2014) Mol Cancer Res 12(8): 1100-11
    › Primary publication · 24759089 (PubMed)
  16. Fibrin accumulation secondary to loss of plasmin-mediated fibrinolysis drives inflammatory osteoporosis in mice. Cole HA, Ohba T, Nyman JS, Hirotaka H, Cates JM, Flick MJ, Degen JL, Schoenecker JG (2014) Arthritis Rheumatol 66(8): 2222-33
    › Primary publication · 24664548 (PubMed) · PMC4474376 (PubMed Central)
  17. Pleiotropic effects of bisphosphonates on osteosarcoma. Ohba T, Cates JM, Cole HA, Slosky DA, Haro H, Ichikawa J, Ando T, Schwartz HS, Schoenecker JG (2014) Bone : 110-20
    › Primary publication · 24636958 (PubMed)
  18. Jagged1 is essential for osteoblast development during maxillary ossification. Hill CR, Yuasa M, Schoenecker J, Goudy SL (2014) Bone : 10-21
    › Primary publication · 24491691 (PubMed) · PMC4306467 (PubMed Central)
  19. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. Ohba T, Cole HA, Cates JM, Slosky DA, Haro H, Ando T, Schwartz HS, Schoenecker JG (2014) J Bone Miner Res 29(6): 1431-45
    › Primary publication · 24443409 (PubMed)
  20. Medial approach for drainage of the obturator musculature in children. Menge TJ, Cole HA, Mignemi ME, Corn WC, Martus JE, Lovejoy SA, Stutz CM, Mencio GA, Schoenecker JG (2014) J Pediatr Orthop 34(3): 307-15
    › Primary publication · 24276231 (PubMed)
  21. Epidemiology, diagnosis, and treatment of pericapsular pyomyositis of the hip in children. Mignemi ME, Menge TJ, Cole HA, Mencio GA, Martus JE, Lovejoy S, Stutz CM, Schoenecker JG (2014) J Pediatr Orthop 34(3): 316-25
    › Primary publication · 24172679 (PubMed)
  22. Complications and outcomes of diaphyseal forearm fracture intramedullary nailing: a comparison of pediatric and adolescent age groups. Martus JE, Preston RK, Schoenecker JG, Lovejoy SA, Green NE, Mencio GA (2013) J Pediatr Orthop 33(6): 598-607
    › Primary publication · 23872805 (PubMed)
  23. Pathologic hip morphology in cerebral palsy and Down syndrome. Schoenecker JG (2013) J Pediatr Orthop : S29-32
    › Primary publication · 23764790 (PubMed)
  24. Implant contamination during spine surgery. Bible JE, O'Neill KR, Crosby CG, Schoenecker JG, McGirt MJ, Devin CJ (2013) Spine J 13(6): 637-40
    › Primary publication · 23321148 (PubMed)
  25. Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets. Duvernay M, Young S, Gailani D, Schoenecker J, Hamm HE, Hamm H (2013) Mol Pharmacol 83(4): 781-92
    › Primary publication · 23307185 (PubMed) · PMC3608438 (PubMed Central)
  26. The spectrum of group A streptococcal joint pathology in the acute care setting. Mignemi ME, Martus JE, Bracikowski AC, Lovejoy SA, Mencio GA, Schoenecker JG (2012) Pediatr Emerg Care 28(11): 1185-9
    › Primary publication · 23114245 (PubMed)
  27. Differential development of the distal and proximal femoral epiphysis and physis in mice. Cole HA, Yuasa M, Hawley G, Cates JM, Nyman JS, Schoenecker JG (2013) Bone 52(1): 337-46
    › Primary publication · 23079139 (PubMed)
  28. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors. Mignemi NA, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, Homlar KC, Correa H, Coffin CM, Black JO, Yi Y, Halpern JL, Holt GE, Schwartz HS, Schoenecker JG, Cates JM (2012) Cancer Sci 103(12): 2173-80
    › Primary publication · 23035734 (PubMed) · PMC4278584 (PubMed Central)
  29. Coagulopathies in orthopaedics: links to inflammation and the potential of individualizing treatment strategies. Stutz CM, O'Rear LD, O'Neill KR, Tamborski ME, Crosby CG, Devin CJ, Schoenecker JG (2013) J Orthop Trauma 27(4): 236-41
    › Primary publication · 22874115 (PubMed)
  30. Pediatric variants of the transolecranon fracture dislocation: recognition and tension band fixation: report of 3 cases. Butler MA, Martus JE, Schoenecker JG (2012) J Hand Surg Am 37(5): 999-1002
    › Primary publication · 22541155 (PubMed)
  31. Micro-computed tomography assessment of the progression of fracture healing in mice. O'Neill KR, Stutz CM, Mignemi NA, Burns MC, Murry MR, Nyman JS, Schoenecker JG (2012) Bone 50(6): 1357-67
    › Primary publication · 22453081 (PubMed)
  32. Supraclavicular nerve entrapment and clavicular fracture. OʼNeill K, Stutz C, Duvernay M, Schoenecker J (2012) J Orthop Trauma 26(6): e63-5
    › Primary publication · 22430514 (PubMed)
  33. Acetabular retroversion in Down syndrome. Sankar WN, Schoenecker JG, Mayfield ME, Kim YJ, Millis MB (2012) J Pediatr Orthop 32(3): 277-81
    › Primary publication · 22411334 (PubMed)
  34. Fracture healing in protease-activated receptor-2 deficient mice. O'Neill KR, Stutz CM, Mignemi NA, Cole H, Murry MR, Nyman JS, Hamm H, Schoenecker JG (2012) J Orthop Res 30(8): 1271-6
    › Primary publication · 22247070 (PubMed)
  35. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma. Ichikawa J, Cole HA, Magnussen RA, Mignemi NA, Butler M, Holt GE, O'Rear L, Yuasa M, Pabla B, Haro H, Cates JM, Hamm HE, Schwartz HS, Schoenecker JG (2012) Cancer 118(9): 2494-506
    › Primary publication · 21953059 (PubMed)
  36. Microscope sterility during spine surgery. Bible JE, O'Neill KR, Crosby CG, Schoenecker JG, McGirt MJ, Devin CJ (2012) Spine (Phila Pa 1976) 37(7): 623-7
    › Primary publication · 21681131 (PubMed)
  37. Quantifying intra-osseous growth of osteosarcoma in a murine model with radiographic analysis. Cole HA, Ichikawa J, Colvin DC, O'Rear L, Schoenecker JG (2011) J Orthop Res 29(12): 1957-62
    › Primary publication · 21656849 (PubMed)
  38. Spica MRI after closed reduction for developmental dysplasia of the hip. Desai AA, Martus JE, Schoenecker J, Kan JH (2011) Pediatr Radiol 41(4): 525-9
    › Primary publication · 21279341 (PubMed)
  39. 2010 Young Investigator Award winner: Therapeutic aprotinin stimulates osteoblast proliferation but inhibits differentiation and bone matrix mineralization. Schoenecker J, Mignemi N, Stutz C, Liu Q, Edwards J, Lynch C, Holt G, Schwartz H, Mencio G, Hamm H (2010) Spine (Phila Pa 1976) 35(9): 1008-16
    › Primary publication · 20407341 (PubMed)
  40. Treatment of traumatic separation of the proximal femoral epiphysis without development of osteonecrosis: a report of two cases. Schoenecker JG, Kim YJ, Ganz R (2010) J Bone Joint Surg Am 92(4): 973-7
    › Primary publication · 20360524 (PubMed)
  41. Relative purity of thrombin-based hemostatic agents used in surgery. Schoenecker JG, Johnson RK, Fields RC, Lesher AP, Domzalski T, Baig K, Lawson JH, Parker W (2003) J Am Coll Surg 197(4): 580-90
    › Primary publication · 14522327 (PubMed)
  42. Protease-activated receptor-2 signaling triggers dendritic cell development. Fields RC, Schoenecker JG, Hart JP, Hoffman MR, Pizzo SV, Lawson JH (2003) Am J Pathol 162(6): 1817-22
    › Primary publication · 12759239 (PubMed) · PMC1868121 (PubMed Central)
  43. Exposure of mice to topical bovine thrombin induces systemic autoimmunity. Schoenecker JG, Johnson RK, Lesher AP, Day JD, Love SD, Hoffman MR, Ortel TL, Parker W, Lawson JH (2001) Am J Pathol 159(5): 1957-69
    › Primary publication · 11696457 (PubMed) · PMC1867043 (PubMed Central)
  44. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose. Schoenecker JG, Hauck RK, Mercer MC, Parker W, Lawson JH (2000) J Clin Immunol 20(6): 434-44
    › Primary publication · 11202233 (PubMed)
  45. Coordinate synthesis and turnover of heat shock proteins in Borrelia burgdorferi: degradation of DnaK during recovery from heat shock. Cluss RG, Goel AS, Rehm HL, Schoenecker JG, Boothby JT (1996) Infect Immun 64(5): 1736-43
    › Primary publication · 8613385 (PubMed) · PMC173986 (PubMed Central)